治疗前肿瘤NECTIN4 RNA表达与一线Enfortumab Vedotin联合帕博利珠单抗治疗转移性尿路上皮癌疗效相关
本研究回顾性分析322例接受一线EV联合帕博利珠单抗治疗的转移性尿路上皮癌患者,评估肿瘤NECTIN4 RNA表达和TMB与疗效的关系。结果显示NECTIN4高表达组和TMB高表达组的总生存期和最佳总体缓解均更优,且NECTIN4表达独立预测OS和BOR;而在帕博利珠单抗单药队列中未见显著关联。
要点
- NECTIN4高表达组较低于组OS延长(中位21.5 vs 14.2个月,HR 0.67)且ORR更高(67.4% vs 41.9%)。
- TMB高表达组也显示更优OS(HR 0.57)和BOR(OR 2.26)。
- NECTIN4高和/或TMB高表达者较双低者OS和BOR更优,双低肿瘤缓解可能性最低。
核心结论
- 治疗前肿瘤NECTIN4 RNA表达与一线EV联合帕博利珠单抗治疗的疗效相关,NECTIN4低表达且TMB低表达肿瘤的缓解可能性最低。
研究设计与样本
- 回顾性研究,纳入接受一线EV联合帕博利珠单抗治疗的转移性尿路上皮癌真实世界队列322例;另分析一线帕博利珠单抗单药队列232例。
主要发现
- NECTIN4高表达组相比低表达组:OS HR 0.67(95%CI 0.46-0.98),中位OS 21.5个月(95%CI 16.2-24.3) vs 14.2个月(95%CI 12.6-23.8);BOR OR 2.98(95%CI 1.68-5.3),ORR 67.4% vs 41.9%。
- TMB高表达组相比低表达组:OS HR 0.57(95%CI 0.33-0.96),中位OS 22.8个月(95%CI 21.5-未达到) vs 15.9个月(95%CI 13.6-19.1);BOR OR 2.26(95%CI 1.14-4.47),ORR 69.2% vs 52.6%。
- 多变量分析中,NECTIN4表达独立预测OS(校正HR 0.62,95%CI 0.41-0.93)和BOR(校正OR 2.64,95%CI 1.4-4.97)。
- NECTIN4高和/或TMB高表达肿瘤患者相比双低者:OS HR 0.61(95%CI 0.42-0.88),BOR OR 3.09(95%CI 1.72-5.54)。
- 在帕博利珠单抗单药队列中,NECTIN4表达与结局无显著关联。
临床怎么用
- 治疗前检测肿瘤NECTIN4 RNA表达和TMB可能有助于识别从一线EV联合帕博利珠单抗治疗中获益更多的转移性尿路上皮癌患者,NECTIN4低且TMB低者缓解可能性最低。
局限性
- 回顾性研究设计。
- 真实世界队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enfortumab vedotin (EV) + pembrolizumab (P; EV + P) is the preferred first-line standard-of-care treatment for metastatic urothelial carcinoma (mUC), yet predictive biomarkers remain lacking. We retrospectively investigated whether tumor NECTIN4 RNA expression and tumor mutational burden (TMB) are associated with outcomes in a real-world mUC cohort receiving first-line EV + P (N = 322). NECTIN4-high subgroup showed more favorable overall survival (OS; hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.46-0.98; median 21.5 mo [95% CI 16.2-24.3] vs 14.2 mo [95% CI 12.6-23.8]) and best overall response (BOR; odds ratio [OR] 2.98, 95% CI 1.68-5.3; objective response rate [ORR]; 67.4% vs 41.9%) than NECTIN4-low subgroup. TMB-high subgroup also showed more favorable OS (HR 0.57, 95% CI 0.33-0.96; median 22.8 mo [95% CI 21.5 to not reached] vs 15.9 mo [95% CI 13.6-19.1]) and BOR (OR 2.26, 95% CI 1.14-4.47; ORR; 69.2% vs 52.6%) than TMB-low subgroup. In multivariable analyses, NECTIN4 expression independently predicted OS (adjusted HR 0.62, 95% CI 0.41-0.93) and BOR (adjusted OR 2.64, 95% CI 1.4-4.97). Patients with NECTIN4-high and/or TMB-high tumors had more favorable OS (HR 0.61, 95% CI 0.42-0.88) and BOR (OR 3.09, 95% CI 1.72-5.54) than those with double-low tumors. In contrast, NECTIN4 expression was not significantly associated with outcomes in the first-line P monotherapy cohort (N = 232). Overall, pretreatment tumor NECTIN4 RNA expression was associated with EV + P efficacy, with NECTIN4-low and TMB-low tumors showing the lowest likelihood of response.
引用
- Cho BA, Perry CJ, Yoo SK, et al. Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer. Eur Urol. 2026. PMID: 42786066. doi:10.1016/j.eururo.2026.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。